Drugs / HiCM-188
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04982081 | Sep 2021 → Dec 2022 | congestive heart failure, dilated cardiomyopathy | HELP Therapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07471698 | Oct 2026 → Oct 2028 expected | heart failure | HELP Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07646210 | Sep 2026 → May 2028 expected | advanced heart failure | HELP Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06866600 | Mar 2025 → Dec 2027 expected | advanced heart failure | HELP Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06340048 | Sep 2023 → Nov 2026 expected | heart failure | HELP Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07496372 | Apr 2026 → Jun 2027 expected | heart failure | HELP Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HiCM-188 | “This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially...” NCT06866600 ↗5“Patients with severe congestive heart failure will be treated with allogeneic human iPSC-derived cardiomyocytes (HiCM-188) through the catheter-based injections.” NCT04982081 ↗ |
| Modality | Cell therapy | “human iPSC-derived cardiomyocytes” NCT04982081 ↗ |
| Route | Other | “through a transcatheter endocardial injection system” NCT04982081 ↗ |